- Guide to PHARMACOLOGY
Synonyms: CP-1044-J3 | Paraderm® | Parfenac®
bufexamac is an approved drug
Compound class: Synthetic organic
Comment: In addition to inhibition of COX enzymes, this drug has been discovered to inhibit class IIb HDACs (ie HDACs 6 and 10) .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G et al.. (2011)
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.
Nat Biotechnol, 29 (3): 255-65. [PMID:21258344]
2. Trommer H, Plätzer M, Raith K, Wohlrab W, Podhaisky HP, Neubert RH. (2003)
Examinations of the antioxidative properties of the topically administered drug bufexamac reveal new insights into its mechanism of action.
J Pharm Pharmacol, 55 (10): 1379-88. [PMID:14607020]